Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bupivacaine + carbopol hydrogel is an investigational sustained-release formulation of the local anesthetic bupivacaine. It utilizes a carbopol-based hydrogel (such as Carbopol 934) as a biodegradable and biocompatible delivery system to provide localized analgesia. By entrapping bupivacaine within the cross-linked polymer matrix, the formulation aims to prolong the duration of pain relief and reduce the need for systemic analgesics, including opioids, following surgical procedures. It has been specifically evaluated in clinical trials for postoperative pain management after mandibular third molar extractions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + carbopol hydrogel.